Becker's Healthcare February 26, 2024
GLP-1 drugs and artificial intelligence are helping people and organizations, respectively, slim down. And people are reluctant to credit them entirely for the results.
“Nobody I know is on Ozempic. Yet, nearly everyone I know is on Ozempic,” Scott Galloway, professor of marketing at NYU Stern School of Business, begins his Feb. 23 essay, “Corporate Ozempic.”
Mr. Galloway posits that people are hesitant to credit a drug for losing those last 15 pounds — doing so “doesn’t fit with our narrative that success is correlated to self-control,” he writes. Similarly, he points to large companies — particularly those in tech — trimming their workforces and posting big profits, but being coy about AI’s contributions toward both.
Companies planned 721,677...
Today's Sponsors
Today's Sponsor